Logo image of BDSX

BIODESIX INC (BDSX) Stock Fundamental Analysis

NASDAQ:BDSX - Nasdaq - US09075X1081 - Common Stock - Currency: USD

0.5245  -0.01 (-1.04%)

Fundamental Rating

3

BDSX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 102 industry peers in the Health Care Providers & Services industry. BDSX may be in some trouble as it scores bad on both profitability and health. BDSX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDSX had negative earnings in the past year.
BDSX had a negative operating cash flow in the past year.
BDSX had negative earnings in each of the past 5 years.
BDSX had a negative operating cash flow in each of the past 5 years.
BDSX Yearly Net Income VS EBIT VS OCF VS FCFBDSX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -44.15%, BDSX is not doing good in the industry: 88.24% of the companies in the same industry are doing better.
The Return On Equity of BDSX (-205.65%) is worse than 84.31% of its industry peers.
Industry RankSector Rank
ROA -44.15%
ROE -205.65%
ROIC N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
BDSX Yearly ROA, ROE, ROICBDSX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

BDSX has a better Gross Margin (78.17%) than 92.16% of its industry peers.
In the last couple of years the Gross Margin of BDSX has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for BDSX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 78.17%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
BDSX Yearly Profit, Operating, Gross MarginsBDSX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

3

2. Health

2.1 Basic Checks

BDSX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BDSX has been increased compared to 1 year ago.
The number of shares outstanding for BDSX has been increased compared to 5 years ago.
BDSX has a worse debt/assets ratio than last year.
BDSX Yearly Shares OutstandingBDSX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M
BDSX Yearly Total Debt VS Total AssetsBDSX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

BDSX has an Altman-Z score of -6.17. This is a bad value and indicates that BDSX is not financially healthy and even has some risk of bankruptcy.
BDSX has a Altman-Z score of -6.17. This is amonst the worse of the industry: BDSX underperforms 87.25% of its industry peers.
A Debt/Equity ratio of 1.74 is on the high side and indicates that BDSX has dependencies on debt financing.
BDSX's Debt to Equity ratio of 1.74 is on the low side compared to the rest of the industry. BDSX is outperformed by 73.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.74
Debt/FCF N/A
Altman-Z -6.17
ROIC/WACCN/A
WACC11.22%
BDSX Yearly LT Debt VS Equity VS FCFBDSX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

2.3 Liquidity

BDSX has a Current Ratio of 2.76. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of BDSX (2.76) is better than 84.31% of its industry peers.
BDSX has a Quick Ratio of 2.76. This indicates that BDSX is financially healthy and has no problem in meeting its short term obligations.
BDSX has a better Quick ratio (2.76) than 84.31% of its industry peers.
Industry RankSector Rank
Current Ratio 2.76
Quick Ratio 2.76
BDSX Yearly Current Assets VS Current LiabilitesBDSX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 46.15% over the past year.
Looking at the last year, BDSX shows a very strong growth in Revenue. The Revenue has grown by 45.30%.
The Revenue has been growing by 23.78% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
Revenue 1Y (TTM)45.3%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%39.28%

3.2 Future

Based on estimates for the next years, BDSX will show a very strong growth in Earnings Per Share. The EPS will grow by 21.22% on average per year.
The Revenue is expected to grow by 24.85% on average over the next years. This is a very strong growth
EPS Next Y39.97%
EPS Next 2Y26.41%
EPS Next 3Y21.22%
EPS Next 5YN/A
Revenue Next Year31.39%
Revenue Next 2Y27.97%
Revenue Next 3Y24.85%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
BDSX Yearly Revenue VS EstimatesBDSX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 50M 100M
BDSX Yearly EPS VS EstimatesBDSX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -0.5 -1 -1.5

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BDSX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDSX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDSX Price Earnings VS Forward Price EarningsBDSX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDSX Per share dataBDSX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as BDSX's earnings are expected to grow with 21.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.41%
EPS Next 3Y21.22%

More info and screens

0

5. Dividend

5.1 Amount

BDSX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODESIX INC

NASDAQ:BDSX (5/2/2025, 3:40:48 PM)

0.5245

-0.01 (-1.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)03-03 2025-03-03/amc
Earnings (Next)05-07 2025-05-07/amc
Inst Owners35.83%
Inst Owner Change0.01%
Ins Owners26.2%
Ins Owner Change7.82%
Market Cap76.57M
Analysts83.33
Price Target3.16 (502.48%)
Short Float %1.5%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.09%
Min EPS beat(2)6.41%
Max EPS beat(2)11.77%
EPS beat(4)4
Avg EPS beat(4)9.29%
Min EPS beat(4)4.24%
Max EPS beat(4)14.75%
EPS beat(8)8
Avg EPS beat(8)9.56%
EPS beat(12)9
Avg EPS beat(12)3.76%
EPS beat(16)11
Avg EPS beat(16)-0.38%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-4.39%
Max Revenue beat(2)0.74%
Revenue beat(4)3
Avg Revenue beat(4)1.8%
Min Revenue beat(4)-4.39%
Max Revenue beat(4)8.39%
Revenue beat(8)4
Avg Revenue beat(8)-0.87%
Revenue beat(12)6
Avg Revenue beat(12)0.72%
Revenue beat(16)8
Avg Revenue beat(16)-1.92%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)2.86%
EPS NY rev (1m)0%
EPS NY rev (3m)4.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.34%
Revenue NY rev (1m)0.34%
Revenue NY rev (3m)-0.2%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.07
P/FCF N/A
P/OCF N/A
P/B 3.67
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.35
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.36
FCFYN/A
OCF(TTM)-0.33
OCFYN/A
SpS0.49
BVpS0.14
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.15%
ROE -205.65%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 78.17%
FCFM N/A
ROA(3y)-55.74%
ROA(5y)-49.96%
ROE(3y)-553.97%
ROE(5y)-391.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y21.1%
GM growth 5Y0.76%
F-Score4
Asset Turnover0.73
Health
Industry RankSector Rank
Debt/Equity 1.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.59%
Cap/Sales 4.82%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.76
Quick Ratio 2.76
Altman-Z -6.17
F-Score4
WACC11.22%
ROIC/WACCN/A
Cap/Depr(3y)283.54%
Cap/Depr(5y)201.2%
Cap/Sales(3y)20.35%
Cap/Sales(5y)14.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%40%
EPS Next Y39.97%
EPS Next 2Y26.41%
EPS Next 3Y21.22%
EPS Next 5YN/A
Revenue 1Y (TTM)45.3%
Revenue growth 3Y9.37%
Revenue growth 5Y23.78%
Sales Q2Q%39.28%
Revenue Next Year31.39%
Revenue Next 2Y27.97%
Revenue Next 3Y24.85%
Revenue Next 5YN/A
EBIT growth 1Y17.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year82.07%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-13.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.72%
OCF growth 3YN/A
OCF growth 5YN/A